<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868058</url>
  </required_header>
  <id_info>
    <org_study_id>SAPB-ESPB hybrid AAS study</org_study_id>
    <nct_id>NCT04868058</nct_id>
  </id_info>
  <brief_title>Serratus Anterior or Erector Spinae Block for Hybrid Arrhythmia Ablation Surgery</brief_title>
  <official_title>Serratus Anterior Plane Block or Erector Spinae Plane Block Used as an Adjuvant for Hybrid Arrhythmia Ablation Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate differences between single-shot EQUAL ropivacaine&#xD;
      doses of the serratus anterior plane block (SAPB) or erector spinae plane block (ESPB)&#xD;
      injection, when used as adjuvant to treat postoperative pain, after one-stage unilateral&#xD;
      hybrid arrhythmia (atrial fibrillation, ventricular tachycardia, inappropriate sinus node&#xD;
      tachycardia) ablation surgery. The primary outcomes are to evaluate block placement efficacy&#xD;
      in the hybrid surgery setting (total time to block placement in seconds, time to&#xD;
      visualization of location of injection in seconds, adequacy of ropivacaine spread) by&#xD;
      picturing and worst numerical scale pain at rest or moving, using a visual analog pain scale&#xD;
      from 0= no pain to 10= maximal pain, in the first 12 hours after admission to the&#xD;
      post-anaesthesia care unit. Secondary outcomes aim to evaluate to investigate pain location,&#xD;
      additional analgesic consumption and requests, ease of breathing, breathing quality, sleeping&#xD;
      quality and quantity, duration of hospitalisation, and general level of satisfaction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical investigation is an interventional uni-center, prospective, open, randomized,&#xD;
      double arm, blinded to the pain physician and the patient, clinical evaluation.&#xD;
&#xD;
      To ensure the same number of patients in each group, a stratified block randomization will be&#xD;
      performed. A randomization list is generated for each type of arrhythmia. Patients will be&#xD;
      block randomized into two groups: the serratus anterior plane block (SAPB) arm or the erector&#xD;
      spinae plane block (ESPB) arm. As such the nerve block performing physician will be informed&#xD;
      on the nerve block choice just before surgery.&#xD;
&#xD;
      132 consecutive patients. (22 in each group) Single Center study: Universitair Ziekenhuis&#xD;
      Brussel - department of Anesthesiology 3 years Subject will be followed till 3 days&#xD;
      post-procedure&#xD;
&#xD;
      Primary outcome measurement details:&#xD;
&#xD;
      The total time to block placement is obtained by starting a timer after local antiseptic&#xD;
      application, just before puncturing the skin, to full injection of the local anaesthetic&#xD;
      ropivacaine where the timer will be stopped.&#xD;
&#xD;
      In practice: a physician places the nerve block, a nurse anaesthetist manages the patient and&#xD;
      a second nurse assistant records the timing and takes a picture just before drug injection&#xD;
      and after block injection The time to visualization of the optimal location before nerve&#xD;
      block injection is defined as the time needed to find the best place before local anaesthetic&#xD;
      injection.&#xD;
&#xD;
      A picture of the location will be taken just before and after injection (by the second nurse&#xD;
      assistant with an I-phone or similar device and kept with the patient's file Pain assessment&#xD;
      will start 1 h after ICU admission by a different team (ICU nurse- intensive care physician&#xD;
      or pain nurse). The first 24h assessments are blinded to the block performing physician.&#xD;
&#xD;
      Visual- analog- pain scores (0 no pain-10= maximal pain) will be analysed at rest or moving&#xD;
      every 4 h or more depending on the patient's needs/requests for the first 24 h. After this&#xD;
      period pain will be analysed twice daily (morning and afternoon) up to 72 h after start of&#xD;
      surgery or less when dismissed earlier.&#xD;
&#xD;
      Secondary outcome measurements will be recorded after the initial 24h twice/da (morning and&#xD;
      afternoon) by a pain nurse. Written data will be transmitted for storage to REDCAP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This clinical investigation is an interventional uni-center, prospective, open, randomized, double arm, blinded to the pain physician and the patient, clinical evaluation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate block placement efficacy in the hybrid surgery setting specifically time to placement in seconds</measure>
    <time_frame>Time to placement: 1200 seconds</time_frame>
    <description>Time to placement in seconds</description>
  </primary_outcome>
  <primary_outcome>
    <measure>evaluate block placement efficacy in the hybrid surgery setting visualization time of location of injection by picturing</measure>
    <time_frame>Visualisation is done by picturing to confirm adequate block (up 120 seconds)</time_frame>
    <description>visualisation time of location of injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>evaluate block placement efficacy in the hybrid surgery setting adequacy of ropivacaine spread by picturing</measure>
    <time_frame>picturing Confirms time of block placement (up to 300 seconds)</time_frame>
    <description>Block placement efficacy by seeing the ropivacaine spread</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Worst numerical scale pain in the first 12 h after admission to the post-anaesthesia care unit.</measure>
    <time_frame>12 hours</time_frame>
    <description>Maximal pain assesed by visual analog scale ,where 0= no pain 10= maximal pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain location</measure>
    <time_frame>72 hours</time_frame>
    <description>Place of pain: sternal; back, thorax, shoulder, throat, neck</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional analgesic consumption and requests</measure>
    <time_frame>72 hours</time_frame>
    <description>Pain drugs used: paracetamol in grams, piritramide in milligrams, diclofenac in milligrams, aspirin in milligrams, colchicine in grams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ease of breathing, breathing quality</measure>
    <time_frame>72 hours</time_frame>
    <description>Breathing evaluation: superficial, tense, normal, deep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleeping quantity</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of hours slept after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration hospital Stay</measure>
    <time_frame>From 2 to 15 days</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>Will be assessed on screening day or exported up to 2 weeks before screening day.</time_frame>
    <description>BMI or Body mass index is obtained from body weight in kg divided by the square of the length in meter) and is expressed in kg/m2).Exclusion criteria if above &gt; 35 kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ideal body weight</measure>
    <time_frame>Will be assessed on screening day or exported up to 2 weeks before screening day.</time_frame>
    <description>Ideal body weight will be calculated from body weight in kg, length in cm and gender on https://by globalrph.com/medcalc. It is expressed in kg and used for drug dosing</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>1 AF SAPB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atrial fibrillation. Serratus anterior plane block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 AF ESPB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atrial fibrillation. Erector spinae plane block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 VT SAPB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ventricular Tachycardia.Serratus anterior plane block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 VT ESPB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ventricular Tachycardia. Erector spinae plane block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 ISNT SAPB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inappropriate Sinus node tachycardia. Serratus anterior plane block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 ISNT ESPB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inappropriate Sinus node tachycardia. Erector spinae plane block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine injection</intervention_name>
    <description>Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine</description>
    <arm_group_label>1 AF SAPB</arm_group_label>
    <arm_group_label>2 AF ESPB</arm_group_label>
    <arm_group_label>3 VT SAPB</arm_group_label>
    <arm_group_label>4 VT ESPB</arm_group_label>
    <arm_group_label>5 ISNT SAPB</arm_group_label>
    <arm_group_label>6 ISNT ESPB</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-80 years.&#xD;
&#xD;
          2. Provision of signed informed consent prior to any study-specific procedure&#xD;
&#xD;
          3. Selected for Hybrid Rhythm ablation surgery (ISNT, VT, AF)&#xD;
&#xD;
          4. American Society of Anesthesiologist physical Status I to III&#xD;
&#xD;
          5. Dutch, French or English speaking&#xD;
&#xD;
          6. Ability to follow the study protocol&#xD;
&#xD;
          7. BMI &gt; 35 kg/m2 . BMI or Body mass index will be obtained from body weight in kg&#xD;
             divided by the square of the length in meter and is expressed in kg/m2&#xD;
&#xD;
             -&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  a. History of chronic pain or drug treatment abuse&#xD;
&#xD;
               -  b. Depression, psychiatric morbidity or mal-adaptive coping behaviour&#xD;
&#xD;
               -  c. Neuropathy&#xD;
&#xD;
               -  d. Severe anxiety or other mental ailment, taking drugs affecting their capacity&#xD;
                  to assess pain (gabapentin, pregabalin, opiod use)&#xD;
&#xD;
               -  e. Chronic or acute skin infection of the back or the lateral thorax&#xD;
&#xD;
               -  f. Hypersensitivity to ropivacaine&#xD;
&#xD;
               -  g. Severe hepatic, renal , pulmonary or cardiac (EF &lt; 30%) disease or refuse to&#xD;
                  participate to the study..&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vincent J Umbrain, MD, PhD</last_name>
    <phone>02 477 8962</phone>
    <phone_ext>0032</phone_ext>
    <email>vincent.umbrain@uzbrussel.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan Poelaert, MD PhD</last_name>
    <phone>02 477 8962</phone>
    <phone_ext>0032</phone_ext>
    <email>jan.poelaert@uzbrussel.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Verborgh, MD PhD</last_name>
      <phone>04764773145</phone>
      <phone_ext>0032</phone_ext>
      <email>christian.verborgh@uzbrussel.be</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Beckers, MD</last_name>
      <phone>04764763141</phone>
      <phone_ext>0032</phone_ext>
      <email>stefan.beckers@uzbrussel.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arrhythmia</keyword>
  <keyword>Ablation</keyword>
  <keyword>Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

